Betalutin® shows strong clinical profile in relapsed/refractory indolent NHL and follicular lymphoma
Updated data reported at the 59th Annual American Society of Hematology (ASH) meetingOslo, Norway, 11 December 2017 Nordic Nanovector ASA (OSE: NANO) has presented updated results from its LYMRIT 37-01 Phase 1/2 clinical study of Betalutin® (177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory (R/R) indolent NHL (iNHL) at the 59th Annual ASH meeting (9-12 December 2017 in Atlanta, GA, USA). A conference call and audio cast to present the results will take place today at 08:00 CET – details below. The updated data continue to highlight Betalutin®’s strong clinical profile